LISATA (LSTA) Buys Marea Therapeutics and Raises $225 Million in Private Placement
Lisata acquires clinical-stage Marea Therapeutics in a stock-for-stock deal, pairing it with a $225 million financing that leaves legacy holders with 2.39%.
Lisata Therapeutics (LSTA) said it has acquired Marea Therapeutics, a clinical-stage biotechnology company focused on cardioendocrine diseases, and simultaneously agreed to a private placement of Series C non-voting convertible preferred stock expected to bring in roughly $225 million in gross proceeds. The combined company shifts its focus from Lisata's cancer peptide certepetide to Marea's two late-stage clinical candidates.
